Jeevan Scientific: Stellar Q3 Standalone Profit, But 9M Consolidated Loss Widens

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorSatyam Jha|Published at:
Jeevan Scientific: Stellar Q3 Standalone Profit, But 9M Consolidated Loss Widens
Overview

Jeevan Scientific Technology Limited reported a strong Q3 FY26 with standalone net profit soaring 614.1% YoY to ₹230.06 lakhs. However, nine-month consolidated results showed a net loss of ₹80.86 lakhs, a significant deterioration from the prior year's profit. Standalone revenue grew 42.5% YoY in the quarter, while consolidated revenue increased 52.5% YoY.

📉 The Financial Deep Dive

Jeevan Scientific Technology Limited has presented a contrasting financial narrative for the nine months ended December 31, 2025 (9M FY26). While the third quarter (Q3 FY26) showcased robust standalone performance, the consolidated picture for the nine-month period paints a concerning trend of increasing losses.

The Numbers:

  • Standalone Performance: For Q3 FY26, standalone revenue from operations climbed to ₹1,690.66 lakhs, marking a significant 42.5% year-on-year (YoY) increase and a strong 62.1% quarter-on-quarter (QoQ) jump. The Net Profit After Tax (PAT) surged by an impressive 614.1% YoY to ₹230.06 lakhs, a remarkable turnaround from a net loss of ₹8.54 lakhs in Q2 FY26 and a substantial gain from ₹32.25 lakhs in Q3 FY25. Consequently, the standalone PAT margin expanded to 13.6% from 2.7% in the previous year's comparable quarter.
    However, the nine-month period tells a different story. Standalone revenue saw a modest 2.5% YoY growth to ₹3,556.40 lakhs. More critically, standalone net profit plummeted by 92.5% YoY to ₹5.53 lakhs.

  • Consolidated Performance: On a consolidated basis, revenue from operations in Q3 FY26 was ₹1,907.15 lakhs, a healthy 52.5% YoY growth. The consolidated net profit for the quarter stood at ₹240.09 lakhs. This quarterly strength, however, is overshadowed by the nine-month performance. Consolidated results for 9M FY26 registered a net loss of ₹80.86 lakhs, a stark deterioration from a net profit of ₹5.90 lakhs in 9M FY25. The consolidated PAT margin for the nine months was a negative -2.0%.
    The subsidiary, Nayas Laboratories Private Limited, contributed revenues of ₹194.18 lakhs and a net profit of ₹9.50 lakhs in Q3 FY26.

The Quality:

The substantial YoY PAT growth in standalone Q3 FY26 suggests operational efficiencies or perhaps one-off gains. However, the significant decline in standalone PAT over nine months, coupled with the widening consolidated net loss over the same period, indicates persistent cost pressures or underlying issues within the group's operations, particularly concerning the subsidiary.

Risks & Outlook:

The primary concern for investors is the significant divergence between the quarterly standalone performance and the deteriorating nine-month consolidated results. The sustained losses at the consolidated level, despite strong quarterly revenue growth, warrant close scrutiny. Investors will be looking for clarity from management on the factors driving the consolidated losses and a clear strategy to improve overall profitability. The impact of the new Labour Codes was deemed immaterial.

No forward-looking guidance or management commentary from a conference call was provided, leaving the outlook reliant on historical trends and unaddressed concerns.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.